Aimovig (erenumab) Injection

Aimovig (Erenumab) is a monoclonal antibody used for the prevention of migraine. It is specifically designed to target and block the activity of the calcitonin gene-related peptide (CGRP) receptor, which is involved in the transmission of pain and the onset of migraines. Aimovig is available as a subcutaneous injection and is typically administered once a month.

How Aimovig Works

Mechanism of Action:

Aimovig works by blocking the CGRP receptor. CGRP is a neuropeptide that plays a crucial role in migraine pathophysiology. It is released during migraine attacks and contributes to the dilation of blood vessels in the brain, leading to pain and inflammation. By preventing CGRP from binding to its receptor, Aimovig reduces the frequency, duration, and severity of migraine attacks.

1. CGRP Receptor Antagonism: Erenumab, the active ingredient in Aimovig, is a fully human monoclonal antibody that specifically binds to the CGRP receptor, blocking its activation by CGRP. This inhibition prevents the cascade of events that typically lead to a migraine, such as vasodilation and neurogenic inflammation.
2. Migraine Prevention: By targeting the CGRP pathway, Aimovig reduces the likelihood of migraine occurrence. Clinical trials have demonstrated its effectiveness in reducing the number of monthly migraine days in patients with episodic and chronic migraine.

Side Effects

While Aimovig is generally well-tolerated, it may cause side effects in some patients. The severity and incidence of these side effects can vary.

Common Side Effects:

• Injection Site Reactions: Redness, pain, or swelling at the site of injection is the most common side effect.
• Constipation: Some patients may experience constipation, which can sometimes be severe.
• Muscle Cramps or Spasms: Muscle pain or cramps can occur, though this is less common.

Serious Side Effects:

• Hypersensitivity Reactions: Rare but serious allergic reactions, including rash, itching, and anaphylaxis, may occur.
• Hypertension: Increased blood pressure has been reported in some patients, especially those with a history of high blood pressure.
• Cardiovascular Events: While rare, there is a potential risk of cardiovascular issues, such as heart attacks, particularly in those with pre-existing conditions.

Indications

Aimovig is indicated for the preventive treatment of migraines in adults.

Approved Indications:

• Migraine Prevention: Aimovig is approved for the preventive treatment of migraines in adults who experience episodic or chronic migraines.

Contraindications

Aimovig is contraindicated in certain situations where its use could pose a risk to the patient.

Contraindications:

• Hypersensitivity: Aimovig is contraindicated in patients with known hypersensitivity to erenumab or any of the excipients in the formulation.
• Serious Allergic Reactions: Patients who have experienced severe allergic reactions to other monoclonal antibodies should not use Aimovig.
• Pregnancy and Breastfeeding: The safety of Aimovig during pregnancy and breastfeeding has not been established, and its use should be avoided unless absolutely necessary.

Price in Different Countries

The cost of Aimovig can vary depending on the country, healthcare system, and pharmacy. Below is a table providing an overview of the price of Aimovig in different countries.

Country	Price (Per Month Supply)	Reference
United States	$600 – $700	GoodRx
United Kingdom	£450 – £500	NHS UK
Canada	CAD $650 – $750	DrugBank
Australia	AUD $800 – $900	PBS Australia
Germany	€550 – €600	G-BA Germany

Top 5 Global Brands

Several pharmaceutical companies are key players in the production and distribution of migraine treatments like Aimovig.

1. Amgen

• Amgen is the developer of Aimovig and a leader in biotechnology, known for its innovative approach to treating chronic conditions such as migraines.

2. Novartis

• Novartis co-markets Aimovig with Amgen outside of the United States and is a major player in the global pharmaceutical industry.

3. Teva Pharmaceuticals

• Teva produces Ajovy (fremanezumab), another CGRP inhibitor for migraine prevention, and is a key competitor in this therapeutic area.

4. Eli Lilly and Company

• Eli Lilly offers Emgality (galcanezumab), a competing CGRP antagonist, and is a significant global brand in migraine treatment.

5. Pfizer

• Pfizer is known for its wide range of pharmaceutical products and is involved in developing treatments for neurological conditions, including migraine.